Project Grant R01AG102399
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $890K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. a cooperative agreement totaling $1,478,201 on August 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a two-phase clinical drug development program evaluating lamivudine (3TC), a reverse transcriptase inhibitor, as a potential treatment to prevent and slow Alzheimer's disease in people with Down syndrome. The research addresses evidence that aberrant activation of retrotransposons—transposable...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,858,368.00 to Brigham & Women's Hospital Inc. to support research on the role of the SORL1-retromer biology in the pathogenesis of Alzheimer's disease. The award has an initial term from September 30, 2024 to August 31, 2027. Brigham & Women's Hospital Inc. is a prominent academic medical center and research institution in Boston, Massachusetts, affiliated with Harvard Medical...
- The National Institutes of Health Office of the Director awarded Brigham & Women's Hospital Inc. $1.602718 million on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a Phase 1 clinical trial evaluating nicotinamide mononucleotide (NMN), a NAD+ precursor, for safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with Down syndrome as a potential intervention to prevent or slow Alzheimer's disease progression. The trial employs a...
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. $751,786 on July 15, 2026, under the Aging Research program (CFDA 93.866) to identify genetic and plasma biomarkers that predict individual response to anti-amyloid-beta monoclonal antibody therapies for Alzheimer's disease. The project will investigate whether plasma biomarkers and microglia/astrocyte-specific polygenic Alzheimer's disease risk variants can predict amyloid-beta clearance, amyloid-related imaging...
- The National Institute on Aging awarded The Washington University $406,707 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a national longitudinal study examining whether integrated dual-eligible special needs plans improve health outcomes for adults with intellectual disabilities and dementia who are dually enrolled in Medicare and Medicaid. The study addresses the absence of national research on dementia care access, quality, and outcomes among...
- The National Institute on Aging, within the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $429,000 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how overexpression of human chromosome 21 (HSA21) orthologs affects neurodegeneration during aging in Caenorhabditis elegans. The project addresses variability in dementia onset among individuals with Down syndrome, which results from trisomy 21. While approximately 75...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $3,481,644 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mechanisms by which excessive amyloid-beta peptides impair brain lymphatic function and contribute to Alzheimer's disease and Down syndrome. The research program comprises three strategic aims. The first involves extensive molecular, cellular, structural, and functional analyses of brain lymphatics in mouse models of...
- Federal Grant Award Summary Brigham & Women's Hospital received a $3.69 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 15, 2025, with a completion date of September 14, 2029. The award funds development of specialized large language models (LLMs) designed to extract Alzheimer's disease and related dementias (ADRD)-relevant clinical phenotypes from electronic health records (EHRs). The project addresses a critical...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- The National Institute on Aging awarded Brigham & Women's Hospital Inc. $943,368 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate health care contact days—days older adults spend obtaining health care outside the home—and their impact on patient outcomes. The research addresses three primary aims. Aim 1 employs semi-structured interviews and focus groups across two large health systems serving multiple populations in five states to elicit perspectives...